It is too early to consider widespread use of a second COVID-19 vaccine booster dose, according to the European Centre for Disease Prevention and Control (ECDC) and EMA's COVID-19 task forc
For many years, those inside the pharma industry have been telling the same old story about innovation: pharma is big, slow, and risk averse. Start-ups move fast and break things.
The National Institutes of Health (NIH) is funding a nationwide study in the US to support research on long-COVID, chronic COVID, or as it's scientifically known, post-acute sequelae of SAR
Little more than a decade ago, the concept of digital twins in life science research may have sounded more like science fiction than a viable model for research and development (R&D).
CureVac and GlaxoSmithKline's first attempt to develop a COVID-19 vaccine was a salutary reminder of the pitfalls in drug development, as the mRNA shot crashed and burned in a clinical tria